RxDoctor Payments Data

Milan Anadkat, MD

Dermatology · Saint Louis, MONPI 1639267149

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $97,889 of the $129,067 with a category attached, or 75.8%. 12 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 29.7% of the total. Among dermatology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$129,067in general payments, 2019–2025

Across 126 payments — averaging $1024.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$38K
  • Boehringer Ingelheim$27K
  • Eli Lilly$23K
  • UCB, Inc.$19K
  • Novocure Inc.$12K
  • Novartis$4K
  • plus $6K from 6 others
$2,312,740in research payments, 2019–2025

Across 727 payments — averaging $3181.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$551K
  • Incyte Corporation$536K
  • UCB SA$321K
  • AbbVie$296K
  • Novartis$185K
  • Boehringer Ingelheim$105K
  • plus $318K from 9 others

What the payments were for

  • Consulting fees$97,88976%
  • Speaking & faculty fees$23,29818%
  • Travel & lodging$6,3025%
  • Food & beverage$1,5621%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim International GmbH42$38,272
Boehringer Ingelheim26$27,239
Eli Lilly12$22,927
UCB, Inc.10$18,649
Novocure Inc.14$11,781
Novartis12$4,059
Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda.1$2,500
UCB SA3$1,829
AbbVie1$1,725
Regeneron Healthcare Solutions, Inc.2$45
Lilly USA, LLC2$25
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,067 in reported general payments places this provider in the 90th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$152,961
Medicare patients
719
Services billed
2,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa21$461,679
Humira(Cf)Adalimumab19$345,274
Cosentyx Unoready PenSecukinumab16$254,341
Humira(Cf) PenAdalimumab18$230,276
OtezlaApremilast46$218,740
Dupixent PenDupilumab55$206,641
Cosentyx Sensoready (2 Pens)Secukinumab12$103,243
Dupixent SyringeDupilumab21$92,712
Acitretin72$16,324
Clobetasol Propionate167$7,764
Fluorouracil104$7,471
Doxycycline Hyclate148$4,920
Tacrolimus23$3,664
Ketoconazole136$2,858
Clindamycin Phosphate67$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf)$1,725$345,27419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 263 dermatology providers in Missouri.

Other dermatology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →